THROMBATE III Rx
Generic Name and Formulations:
Antithrombin III (human) 500 IU, 1000 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Grifols Biologicals, Inc.
Indications for THROMBATE III:
Treatment of patients with hereditary antithrombin III deficiency (AT-III) in surgical or obstetrical procedures and thromboembolism.
Give by IV infusion over 10–20 minutes. Individualized. Dose (units required)= [desired (% of normal) – baseline (% of normal) AT-III level] X weight (kg)/1.4. Loading dose: increase AT-III to 120% of normal. Subsequent dose should be based on AT-III levels obtained 20 minutes post-infusion, every 12hrs, and before the next dose. Maintain AT-III levels at 80–120% of normal for 2–8 days.
Surgery. Hemorrhage. Acute thrombosis. Monitor AT-III levels during treatment. Contains human plasma; monitor for possible infection transmission. Pregnancy (Cat.B).
Potentiates anticoagulant effect of heparin; reduce heparin dose.
Thrombin inhibitor (α2-glycoprotein).
Dizziness, chest tightness, nausea, taste disturbances, chills, cramps, shortness of breath, chest pain, light-headedness, bowel fullness, hives, fever, hematoma formation.
Report all infections suspected to be transmitted by Thrombate III to (800) 520-2807.
Single-use vial—1 (w. diluent, needles)
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|